Botulinum toxin type a in the treatment of dermatochalasis: an open-label, randomized, dose-comparison study
Cohen, J.L.; Dayan, S.H.
Journal of Drugs in Dermatology Jdd 5(7): 596-601
2006
ISSN/ISBN: 1545-9616 PMID: 16865863 Document Number: 8386
To compare the efficacy and safety of 2 doses of botulinum toxin type A in the treatment of dermatochalasis. Forty patients with mild to moderate dermatochalasis were randomly assigned to receive 1 of 2 doses of botulinum toxin type A in the lateral infrabrow--4 U/brow or 6 U/brow--and followed up for 20 weeks. Investigator assessment showed the proportion of responders (> or = 1 grade improvement in severity of dermatochalasis on a scale of none, mild, moderate, or severe) at week 2 was 32% with 4 U and 47% with 6 U. Compared with the lower dose group, the higher dose group also reported a greater degree of improvement, significantly higher ratings for feelings of attractiveness and feelings of satisfaction with appearance, and a higher incidence of satisfaction. Single-site injection of botulinum toxin type A in the lateral infrabrow can offer effective treatment for mild to moderate upper eyelid dermatochalasis.
Document emailed within 1 workday
